Manufacturer of Controlled Substances, Notice of Registration, AMRI Rensselaer, Inc., 75670-75671 [2012-30780]
Download as PDF
<![CDATA[
75670
Federal Register / Vol. 77, No. 246 / Friday, December 21, 2012 / Notices
Portland, OR; VicTrack, Docklands,
AUSTRALIA; VIP Operator, Skopje,
MACEDONIA; Virtus IT Limited,
London, UNITED KINGDOM; VISITEK,
Jakarta Selatan, INDONESIA; Vitria
Technology, Inc., Sunnyvale, CA;
Vonage, Holmdel, NJ; Wataniya
Telecom Kuwait, Plot 1A, Sharq Area,
KUWAIT; Wind Telecomunicazioni
SpA, Roma, ITALY; WiTech, Cascina,
ITALY; Xelas software, Marina del Rey,
CA; XTRAC, LLC, Boston, MA; Yyield
Group BV, Bennebroek,
NETHERLANDS; Zain, Safat, KUWAIT;
ZAO ‘‘Glasnet’’, Korolev, RUSSIA;
Zenoss, Annapolis, MD and Zenulta
Limited, Swindon, UNITED KINGDOM.
No other changes have been made in
either the membership or planned
activity of the group research project.
Membership in this group research
project remains open, and The Forum
intends to file additional written
notifications disclosing all changes in
membership.
On October 21, 1988, The Forum filed
its original notification pursuant to
Section 6(a) of the Act. The Department
of Justice published a notice in the
Federal Register pursuant to Section
6(b) of the Act on December 8, 1988 (53
FR 49615).
The last notification was filed with
the Department on August 22, 2011. A
notice was published in the Federal
Register pursuant to Section 6(b) of the
Act on November 18, 2011 (76 FR
71602).
Patricia A. Brink,
Director of Civil Enforcement, Antitrust
Division.
such basic class of controlled substance
may file comments or objections to the
issuance of the proposed registration
and may, at the same time, file a written
request for a hearing on such
application pursuant to 21 CFR 1301.43,
and in such form as prescribed by 21
CFR 1316.47.
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than January 22, 2013.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
40 FR 43745–46, all applicants for
registration to import a basic class of
any controlled substance in schedules I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: December 14, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2012–30782 Filed 12–20–12; 8:45 am]
BILLING CODE 4410–09–P
[FR Doc. 2012–30724 Filed 12–20–12; 8:45 am]
BILLING CODE P
DEPARTMENT OF JUSTICE
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration; Fisher Clinical
Services,Inc.
mstockstill on DSK4VPTVN1PROD with
Importer of Controlled Substances,
Notice of Application, Hospira
Pursuant to Title 21 Code of Federal
Regulations 1301.34(a), this is notice
that on September 20, 2012, Hospira,
1776 North Centennial Drive,
McPherson, Kansas 67460–1247, made
application by renewal to the Drug
Enforcement Administration (DEA) for
registration as an importer of
Remifentanil (9739), a basic class of
controlled substance listed in schedule
II.
The company plans to import
Remifentanil for use in dosage form
manufacturing.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
VerDate Mar<15>2010
18:28 Dec 20, 2012
Jkt 229001
By Notice dated September 20, 2012,
and published in the Federal Register
on October 2, 2012, 77 FR 60143, Fisher
Clinical Services, Inc., 7554 Schantz
Road, Allentown, Pennsylvania 18106,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as an importer of
noroxymorphone (9668), a basic class of
controlled substance in schedule II.
The company plans to import the
listed substances for analytical research
and clinical trials.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a)
and determined that the registration of
Fisher Clinical Services, Inc., to import
PO 00000
Frm 00065
Fmt 4703
Sfmt 4703
the basic class of controlled substance is
consistent with the public interest and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971. DEA
has investigated Fisher Clinical
Services, Inc., to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems; verification of the
company’s compliance with state and
local laws; and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C.
952(a) and 958(a), and in accordance
with 21 CFR 1301.34, the above named
company is granted registration as an
importer of the basic class of controlled
substance listed.
Dated: December 14, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2012–30784 Filed 12–20–12; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances, Notice of Registration,
AMRI Rensselaer, Inc.
By Notice dated July 30, 2012, and
published in the Federal Register on
August 7, 2012, 77 FR 47114, AMRI
Rensselaer, Inc., 33 Riverside Avenue,
Rensselaer, New York 12144, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the following basic classes of controlled
substances:
Drug
Marihuana (7360) .........................
Tetrahydrocannabinols (7370) .....
Amphetamine (1100) ....................
Lisdexamfetamine (1205) .............
Methylphenidate (1724) ................
Pentobarbital (2270) .....................
4-Anilino-N-phenethyl-4-piperidine
(8333).
Meperidine (9230) ........................
Fentanyl (9801) ............................
Schedule
I
I
II
II
II
II
II
II
II
The company plans to manufacture
bulk controlled substances for use in
product development and for
distribution to its customers.
In reference to drug code 7360
(Marihuana), the company plans to bulk
manufacture cannabidiol as a synthetic
intermediate. This controlled substance
E:\FR\FM\21DEN1.SGM
21DEN1
75671
Federal Register / Vol. 77, No. 246 / Friday, December 21, 2012 / Notices
will be further synthesized to bulk
manufacture a synthetic THC (7370). No
other activity for this drug code is
authorized for this registration.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a), and
determined that the registration of
AMRI Rensselaer, Inc., to manufacture
the listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated AMRI Rensselaer, Inc., to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: December 18, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
mstockstill on DSK4VPTVN1PROD with
Manufacturer of Controlled
Substances; Notice of Registration;
Rhodes Technologies
Jkt 229001
[FR Doc. 2012–30785 Filed 12–20–12; 8:45 am]
BILLING CODE 4410–09–P
Inc., to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems; verification
of the company’s compliance with state
and local laws; and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C.
823(a), and in accordance with 21 CFR
1301.33, the above named company is
granted registration as a bulk
manufacturer of the basic classes of
controlled substances listed.
Dated: December 14, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2012–30783 Filed 12–20–12; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
DEPARTMENT OF JUSTICE
Manufacturer of Controlled
Substances; Notice of Registration;
Euticals, Inc.
Drug Enforcement Administration
Drug
Manufacturer of Controlled
Substances; Notice of Registration;
Chemtos, LLC
By Notice dated July 30, 2012, and
published in the Federal Register on
August 7, 2012, 77 FR 47116, Chemtos,
LLC, 14101 W. Highway 290, Building
2000B, Austin, Texas 78737–9331, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the following basic classes of controlled
substances:
Schedule
Drug
By Notice dated May 31, 2012, and
published in the Federal Register on
June 8, 2012, 77 FR 34072, Rhodes
Technologies, 498 Washington Street,
Coventry, Rhode Island 02816, made
application to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of morphine (9300),
a basic class of controlled substance
listed in schedule II.
The company plans to manufacture
the listed controlled substance in bulk
for conversion and sale to dosage form
manufacturers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a), and
determined that the registration of
Rhodes Technologies to manufacture
the listed basic class of controlled
substance is consistent with the public
interest at this time. DEA has
investigated Rhodes Technologies to
ensure that the company’s registration is
consistent with the public interest. The
18:28 Dec 20, 2012
Dated: December 14, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
By Notice dated August 17, 2012, and
published in the Federal Register on
August 29, 2012, 77 FR 52367, Euticals,
Inc., (formerly known as Archimica,
Inc.), 2460 W. Bennett Street,
Springfield, Missouri 65807–1229, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the following basic classes of controlled
substances:
[FR Doc. 2012–30780 Filed 12–20–12; 8:45 am]
VerDate Mar<15>2010
investigation has included inspection
and testing of the company’s physical
security systems; verification of the
company’s compliance with state and
local laws; and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C.
823(a), and in accordance with 21 CFR
1301.33, the above named company is
granted registration as a bulk
manufacturer of the basic class of
controlled substance listed.
Gamma
Hydroxybutyric
Acid
(2010).
Amphetamine (1100) ....................
Lisdexamfetamine (1205) .............
Methylphenidate (1724) ................
Phenylacetone (8501) ..................
Methadone Intermediate (9254) ...
Tapentadol (9780) ........................
II
II
II
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution and sale to its
customers.
With regards to amphetamine (1100),
the company plans to acquire the listed
controlled substance in bulk from a
domestic source in order to manufacture
other controlled substances in bulk for
distribution to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a), and
determined that the registration of
Euticals, Inc., to manufacture the listed
basic classes of controlled substances is
consistent with the public interest at
this time. DEA has investigated Euticals,
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
Schedule
I
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Lisdexamfetamine (1205) .............
Methylphenidate (1724) ................
Nabilone (7379) ............................
Phenylacetone (8501) ..................
Cocaine (9041) .............................
Codeine (9050) .............................
Etorphine HCL (9059) ..................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Ecgonine (9180) ...........................
Ethylmorphine (9190) ...................
Hydrocodone (9193) .....................
Levomethorphan (9210) ...............
Levorphanol (9220) ......................
Isomethadone (9226) ...................
Meperidine (9230) ........................
Meperidine-intermediate-A (9232)
Meperidine-intermediate-B (9233)
Meperidine-intermediate-C (9234)
Methadone (9250) ........................
Methadone intermediate (9254) ...
Morphine (9300) ...........................
Thebaine (9333) ...........................
Dihydroetorphine (9334) ...............
Levo-alphacetylmethadol (9648) ..
E:\FR\FM\21DEN1.SGM
21DEN1
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
]]>Agencies
[Federal Register Volume 77, Number 246 (Friday, December 21, 2012)]
[Notices]
[Pages 75670-75671]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-30780]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances, Notice of Registration,
AMRI Rensselaer, Inc.
By Notice dated July 30, 2012, and published in the Federal
Register on August 7, 2012, 77 FR 47114, AMRI Rensselaer, Inc., 33
Riverside Avenue, Rensselaer, New York 12144, made application by
renewal to the Drug Enforcement Administration (DEA) to be registered
as a bulk manufacturer of the following basic classes of controlled
substances:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Marihuana (7360)........................... I
Tetrahydrocannabinols (7370)............... I
Amphetamine (1100)......................... II
Lisdexamfetamine (1205).................... II
Methylphenidate (1724)..................... II
Pentobarbital (2270)....................... II
4-Anilino-N-phenethyl-4-piperidine (8333).. II
Meperidine (9230).......................... II
Fentanyl (9801)............................ II
------------------------------------------------------------------------
The company plans to manufacture bulk controlled substances for use
in product development and for distribution to its customers.
In reference to drug code 7360 (Marihuana), the company plans to
bulk manufacture cannabidiol as a synthetic intermediate. This
controlled substance
[[Page 75671]]
will be further synthesized to bulk manufacture a synthetic THC (7370).
No other activity for this drug code is authorized for this
registration.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a), and determined that the registration
of AMRI Rensselaer, Inc., to manufacture the listed basic classes of
controlled substances is consistent with the public interest at this
time. DEA has investigated AMRI Rensselaer, Inc., to ensure that the
company's registration is consistent with the public interest. The
investigation has included inspection and testing of the company's
physical security systems, verification of the company's compliance
with state and local laws, and a review of the company's background and
history.
Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR
1301.33, the above named company is granted registration as a bulk
manufacturer of the basic classes of controlled substances listed.
Dated: December 18, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2012-30780 Filed 12-20-12; 8:45 am]
BILLING CODE 4410-09-P
